Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling

J. Lackey, J. Barnett, L. Davidson, I. H. Batty, N. R. Leslie, C. P. Downes

    Research output: Contribution to journalArticle

    31 Citations (Scopus)

    Abstract

    Many tumors have chronically elevated activity of PI 3-kinase-dependent signaling pathways, caused largely by oncogenic mutation of PI 3-kinase itself or loss of the opposing tumor suppressor lipid phosphatase, PTEN. Several PI 3-kinase-dependent feedback mechanisms have been identified that may affect the sensitivity of upstream receptor signaling, but the events required to initiate an inhibited state have not been addressed. We show that in a variety of cell types, loss of PTEN via experimental knockdown or in tumor cell lines correlates with a block in insulin-like growth factor 1 (IGF1)/insulin signaling, without affecting the sensitivity of platelet-derived growth factor or epidermal growth factor signaling. These effects on IGF/insulin signaling include a reduction of up to five- to tenfold in IGF-stimulated PI 3-kinase activation, a failure to activate the ERK kinases and, in some cells, reduced expression of insulin receptor substrate 1, and both IGF1 and insulin receptors. These data indicate that chronically elevated PI 3-kinase-dependent signaling to the degree seen in many tumors causes a selective loss of sensitivity in IGF1/insulin signaling that could significantly reduce the selective advantage of deregulated activation of IGF1/IGF1-R signaling in tumor development.
    Original languageEnglish
    Pages (from-to)7132-7142
    Number of pages11
    JournalOncogene
    Volume26
    Issue number50
    DOIs
    Publication statusPublished - Nov 2007

    Fingerprint

    Somatomedins
    Phosphatidylinositol 3-Kinases
    Insulin
    Neoplasms
    PTEN Phosphohydrolase
    Somatomedin Receptors
    Insulin Receptor Substrate Proteins
    Platelet-Derived Growth Factor
    Insulin Receptor
    Tumor Cell Line
    Epidermal Growth Factor
    Phosphotransferases
    Lipids
    Mutation

    Keywords

    • Phosphatase
    • Signal transduction
    • Insulin-like growth factor
    • Phosphoinositide
    • Tumour suppressor

    Cite this

    Lackey, J., Barnett, J., Davidson, L., Batty, I. H., Leslie, N. R., & Downes, C. P. (2007). Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. Oncogene, 26(50), 7132-7142. https://doi.org/10.1038/sj.onc.1210520
    Lackey, J. ; Barnett, J. ; Davidson, L. ; Batty, I. H. ; Leslie, N. R. ; Downes, C. P. / Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. In: Oncogene. 2007 ; Vol. 26, No. 50. pp. 7132-7142.
    @article{fd6c25b669994343b3c50bc52b8e0e69,
    title = "Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling",
    abstract = "Many tumors have chronically elevated activity of PI 3-kinase-dependent signaling pathways, caused largely by oncogenic mutation of PI 3-kinase itself or loss of the opposing tumor suppressor lipid phosphatase, PTEN. Several PI 3-kinase-dependent feedback mechanisms have been identified that may affect the sensitivity of upstream receptor signaling, but the events required to initiate an inhibited state have not been addressed. We show that in a variety of cell types, loss of PTEN via experimental knockdown or in tumor cell lines correlates with a block in insulin-like growth factor 1 (IGF1)/insulin signaling, without affecting the sensitivity of platelet-derived growth factor or epidermal growth factor signaling. These effects on IGF/insulin signaling include a reduction of up to five- to tenfold in IGF-stimulated PI 3-kinase activation, a failure to activate the ERK kinases and, in some cells, reduced expression of insulin receptor substrate 1, and both IGF1 and insulin receptors. These data indicate that chronically elevated PI 3-kinase-dependent signaling to the degree seen in many tumors causes a selective loss of sensitivity in IGF1/insulin signaling that could significantly reduce the selective advantage of deregulated activation of IGF1/IGF1-R signaling in tumor development.",
    keywords = "Phosphatase, Signal transduction, Insulin-like growth factor, Phosphoinositide, Tumour suppressor",
    author = "J. Lackey and J. Barnett and L. Davidson and Batty, {I. H.} and Leslie, {N. R.} and Downes, {C. P.}",
    note = "dc.publisher: Nature Publishing Group",
    year = "2007",
    month = "11",
    doi = "10.1038/sj.onc.1210520",
    language = "English",
    volume = "26",
    pages = "7132--7142",
    journal = "Oncogene",
    issn = "0950-9232",
    publisher = "Nature Publishing Group",
    number = "50",

    }

    Lackey, J, Barnett, J, Davidson, L, Batty, IH, Leslie, NR & Downes, CP 2007, 'Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling', Oncogene, vol. 26, no. 50, pp. 7132-7142. https://doi.org/10.1038/sj.onc.1210520

    Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. / Lackey, J.; Barnett, J.; Davidson, L.; Batty, I. H.; Leslie, N. R.; Downes, C. P.

    In: Oncogene, Vol. 26, No. 50, 11.2007, p. 7132-7142.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling

    AU - Lackey, J.

    AU - Barnett, J.

    AU - Davidson, L.

    AU - Batty, I. H.

    AU - Leslie, N. R.

    AU - Downes, C. P.

    N1 - dc.publisher: Nature Publishing Group

    PY - 2007/11

    Y1 - 2007/11

    N2 - Many tumors have chronically elevated activity of PI 3-kinase-dependent signaling pathways, caused largely by oncogenic mutation of PI 3-kinase itself or loss of the opposing tumor suppressor lipid phosphatase, PTEN. Several PI 3-kinase-dependent feedback mechanisms have been identified that may affect the sensitivity of upstream receptor signaling, but the events required to initiate an inhibited state have not been addressed. We show that in a variety of cell types, loss of PTEN via experimental knockdown or in tumor cell lines correlates with a block in insulin-like growth factor 1 (IGF1)/insulin signaling, without affecting the sensitivity of platelet-derived growth factor or epidermal growth factor signaling. These effects on IGF/insulin signaling include a reduction of up to five- to tenfold in IGF-stimulated PI 3-kinase activation, a failure to activate the ERK kinases and, in some cells, reduced expression of insulin receptor substrate 1, and both IGF1 and insulin receptors. These data indicate that chronically elevated PI 3-kinase-dependent signaling to the degree seen in many tumors causes a selective loss of sensitivity in IGF1/insulin signaling that could significantly reduce the selective advantage of deregulated activation of IGF1/IGF1-R signaling in tumor development.

    AB - Many tumors have chronically elevated activity of PI 3-kinase-dependent signaling pathways, caused largely by oncogenic mutation of PI 3-kinase itself or loss of the opposing tumor suppressor lipid phosphatase, PTEN. Several PI 3-kinase-dependent feedback mechanisms have been identified that may affect the sensitivity of upstream receptor signaling, but the events required to initiate an inhibited state have not been addressed. We show that in a variety of cell types, loss of PTEN via experimental knockdown or in tumor cell lines correlates with a block in insulin-like growth factor 1 (IGF1)/insulin signaling, without affecting the sensitivity of platelet-derived growth factor or epidermal growth factor signaling. These effects on IGF/insulin signaling include a reduction of up to five- to tenfold in IGF-stimulated PI 3-kinase activation, a failure to activate the ERK kinases and, in some cells, reduced expression of insulin receptor substrate 1, and both IGF1 and insulin receptors. These data indicate that chronically elevated PI 3-kinase-dependent signaling to the degree seen in many tumors causes a selective loss of sensitivity in IGF1/insulin signaling that could significantly reduce the selective advantage of deregulated activation of IGF1/IGF1-R signaling in tumor development.

    KW - Phosphatase

    KW - Signal transduction

    KW - Insulin-like growth factor

    KW - Phosphoinositide

    KW - Tumour suppressor

    U2 - 10.1038/sj.onc.1210520

    DO - 10.1038/sj.onc.1210520

    M3 - Article

    VL - 26

    SP - 7132

    EP - 7142

    JO - Oncogene

    JF - Oncogene

    SN - 0950-9232

    IS - 50

    ER -